Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAMedia: FDA updates off-patent, off-exclusivity list to encourage drug competition: https://t.co/X2oSkUNpte
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDA_Drug_Info: #FDA issues Draft Guidance on Drug Products, Including Biological Products, that Contain Nanomaterials: https://t.co/8DGVldvwAw.
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: #EveryTryCounts is part of FDA’s efforts to reduce the public health burden of tobacco by encouraging adult smokers… https://t.co/1P1bJOc7Kr
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA releases two new guidance documents to advance modern framework for development of therapies targeted to molecular subtypes of disease https://t.co/kVPubEe2VO
SteveFDA (R-D.C.)
@SGottliebFDA
RT @annaedney: FDA is making moves to inject more competition in the massive insulin market and bring down prices https://t.co/Si0n2T3RbF
SteveFDA (R-D.C.)
@SGottliebFDA
RT @steveusdin1: FDA guides on molecular targeted therapies beyond cancer. The idea is to apply "tissue agnostic" drug development t… https://t.co/71b4SBA1fd
SteveFDA (R-D.C.)
@SGottliebFDA
RT @tmprowell: Seamless designs for oncology drug development explained: https://t.co/YEAywQOyPI @FDAOncology
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA takes new steps to facilitate more competition for “abandoned” generics that lack multiple entrants https://t.co/SG8P0WfO9b
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAOncology: Harnessing the Power of Collaboration - interview with @FDAOncology Richard Pazdur via @ASHClinicalNews https://t.co/AIG21msMkf
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA’s new policy framework will promote development of a paradigm of drugs that target molecular subtypes of disease https://t.co/sWJonLeUZW
SteveFDA (R-D.C.)
@SGottliebFDA
Today: FDA public workshop on patient-focused drug development: collecting comprehensive and representative input on burden of disease and current therapy https://t.co/pjIqEbJ0iM #PFDD
SteveFDA (R-D.C.)
@SGottliebFDA
Watch live: FDA public patient-focused drug development workshop on collecting meaningful patient input throughout the drug development process: https://t.co/MW5UuvSGOd
SteveFDA (R-D.C.)
@SGottliebFDA
RT @RAPSorg: What's Coming in 2018: @US_FDA's Regulatory Agenda | #Regulatory Focus https://t.co/26lPEWPjlg #FDA #pharma #meddevice #biotech
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDA_ORA: Do you suspect criminal activity relating to FDA-regulated products? Report suspected criminal activity to #FDAORA’… https://t.co/CllcnkYj5z
SteveFDA (R-D.C.)
@SGottliebFDA
RT @RAPSorg: Nanomaterials: @US_FDA Issues Draft Guidance for Drugs and Biologics | #Regulatory Focus https://t.co/GwDs11tzwr… https://t.co/UIgkFF4GFB
SteveFDA (R-D.C.)
@SGottliebFDA
RT @maggiemfox: Sometimes, homeopathy is worse than a placebo. @US_FDA says it's going to start better enforcement https://t.co/9IQbBpaZWr
SteveFDA (R-D.C.)
@SGottliebFDA
FDA’s new risk-based approach to oversight of homeopathic products will focus on drugs with harmful ingredients; products making claims to treat serious conditions with no evidence of benefit; drugs that are poorly manufactured and create potential risks
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA’s new risk-based approach to oversight of homeopathic products focuses on drugs with potential to cause harm in absence of any benefit https://t.co/AAR5HcnQdg
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: The Nicotine Steering Committee meets Jan. 26 to discuss therapeutic nicotine product evaluation. � Register to att… https://t.co/pKv6rASk2d